128 related articles for article (PubMed ID: 10410863)
1. Update of diagnostic and prognostic markers in cutaneous malignant melanoma.
Reed JA; Albino AP
Dermatol Clin; 1999 Jul; 17(3):631-43. PubMed ID: 10410863
[TBL] [Abstract][Full Text] [Related]
2. Update of diagnostic and prognostic markers in cutaneous malignant melanoma.
Reed JA; Albino AP
Clin Lab Med; 2000 Dec; 20(4):817-38. PubMed ID: 11221516
[TBL] [Abstract][Full Text] [Related]
3. Importance of P-cadherin, beta-catenin, and Wnt5a/frizzled for progression of melanocytic tumors and prognosis in cutaneous melanoma.
Bachmann IM; Straume O; Puntervoll HE; Kalvenes MB; Akslen LA
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8606-14. PubMed ID: 16361544
[TBL] [Abstract][Full Text] [Related]
4. Tumor progression, early diagnosis and prognosis of melanoma.
Elder D
Acta Oncol; 1999; 38(5):535-47. PubMed ID: 10427941
[TBL] [Abstract][Full Text] [Related]
5. Molecular markers of circulating melanoma cells.
Medic S; Pearce RL; Heenan PJ; Ziman M
Pigment Cell Res; 2007 Apr; 20(2):80-91. PubMed ID: 17371435
[TBL] [Abstract][Full Text] [Related]
6. Molecular prognostic markers in intermediate-thickness cutaneous malignant melanoma.
Hieken TJ; Ronan SG; Farolan M; Shilkaitis AL; Das Gupta TK
Cancer; 1999 Jan; 85(2):375-82. PubMed ID: 10023705
[TBL] [Abstract][Full Text] [Related]
7. Molecular markers in malignant cutaneous melanoma: gift horse or one-trick pony?
Martinez SR; Hoon DS
J Cell Biochem; 2005 Oct; 96(3):473-83. PubMed ID: 16088931
[TBL] [Abstract][Full Text] [Related]
8. Emerging Biomarkers in Cutaneous Melanoma.
Eisenstein A; Gonzalez EC; Raghunathan R; Xu X; Wu M; McLean EO; McGee J; Ryu B; Alani RM
Mol Diagn Ther; 2018 Apr; 22(2):203-218. PubMed ID: 29411301
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous endocrine expression and loss of melanoma markers in malignant melanoma metastases, a retrospective analysis.
Steppert C; Krugmann J; Sterlacci W
Pathol Oncol Res; 2020 Jul; 26(3):1777-1779. PubMed ID: 31654227
[TBL] [Abstract][Full Text] [Related]
10. Microphthalmia transcription factor: not a sensitive or specific marker for the diagnosis of desmoplastic melanoma and spindle cell (non-desmoplastic) melanoma.
Granter SR; Weilbaecher KN; Quigley C; Fletcher CD; Fisher DE
Am J Dermatopathol; 2001 Jun; 23(3):185-9. PubMed ID: 11391097
[TBL] [Abstract][Full Text] [Related]
11. Melanoma long non-coding RNA signature predicts prognostic survival and directs clinical risk-specific treatments.
Chen X; Guo W; Xu XJ; Su F; Wang Y; Zhang Y; Wang Q; Zhu L
J Dermatol Sci; 2017 Mar; 85(3):226-234. PubMed ID: 27955882
[TBL] [Abstract][Full Text] [Related]
12. Molecular oncogene markers and their significance in cutaneous malignant melanoma.
Konstadoulakis MM; Vezeridis M; Hatziyianni E; Karakousis CP; Cole B; Bland KI; Wanebo HJ
Ann Surg Oncol; 1998; 5(3):253-60. PubMed ID: 9607628
[TBL] [Abstract][Full Text] [Related]
13. Malignant melanoma of the auricle.
Mondin V; Rinaldo A; Shaha A; Cureoglu S; Devaney KO; Suárez C; Ferlito A
Acta Otolaryngol; 2005 Nov; 125(11):1140-4. PubMed ID: 16353384
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of circulating melanoma cells detected by reverse transcriptase-polymerase chain reaction.
Palmieri G; Ascierto PA; Perrone F; Satriano SM; Ottaiano A; Daponte A; Napolitano M; Caracò C; Mozzillo N; Melucci MT; Cossu A; Tanda F; Gallo C; Satriano RA; Castello G
J Clin Oncol; 2003 Mar; 21(5):767-73. PubMed ID: 12610172
[TBL] [Abstract][Full Text] [Related]
15. Melanoma progression.
Elder DE
Pathology; 2016 Feb; 48(2):147-54. PubMed ID: 27020387
[TBL] [Abstract][Full Text] [Related]
16. Expression of Melan-A/MART-1 antigen as a prognostic factor in primary cutaneous melanoma.
Berset M; Cerottini JP; Guggisberg D; Romero P; Burri F; Rimoldi D; Panizzon RG
Int J Cancer; 2001 Jan; 95(1):73-7. PubMed ID: 11241315
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic value and prognostic significance of protein S-100beta, melanoma-inhibitory activity, and tyrosinase/MART-1 reverse transcription-polymerase chain reaction in the follow-up of high-risk melanoma patients.
Garbe C; Leiter U; Ellwanger U; Blaheta HJ; Meier F; Rassner G; Schittek B
Cancer; 2003 Apr; 97(7):1737-45. PubMed ID: 12655531
[TBL] [Abstract][Full Text] [Related]
18. Molecular detection of MART-1, tyrosinase and MIA in peripheral blood, lymph nodes and metastatic sites of stage III/IV melanoma patients.
Enk CD; Lotem M; Gimon Z; Hochberg M
Melanoma Res; 2004 Oct; 14(5):361-5. PubMed ID: 15457091
[TBL] [Abstract][Full Text] [Related]
19. p53-protein and Ki-67-antigen expression are both reliable biomarkers of prognosis in thick stage I nodular melanomas of the skin.
Vogt T; Zipperer KH; Vogt A; Hölzel D; Landthaler M; Stolz W
Histopathology; 1997 Jan; 30(1):57-63. PubMed ID: 9023558
[TBL] [Abstract][Full Text] [Related]
20. Intratumoral expression of cyclooxygenase-2 (COX-2) is a negative prognostic marker for patients with cutaneous melanoma.
Kuźbicki Ł; Lange D; Stanek-Widera A; Chwirot BW
Melanoma Res; 2016 Oct; 26(5):448-56. PubMed ID: 27391144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
